JP2006296220A - Method for separating and refining dna or the like and separating and refining mechanism - Google Patents

Method for separating and refining dna or the like and separating and refining mechanism Download PDF

Info

Publication number
JP2006296220A
JP2006296220A JP2005118750A JP2005118750A JP2006296220A JP 2006296220 A JP2006296220 A JP 2006296220A JP 2005118750 A JP2005118750 A JP 2005118750A JP 2005118750 A JP2005118750 A JP 2005118750A JP 2006296220 A JP2006296220 A JP 2006296220A
Authority
JP
Japan
Prior art keywords
monolith
monolith structure
dna
purification
biological sample
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2005118750A
Other languages
Japanese (ja)
Other versions
JP4791750B2 (en
Inventor
Abudogupur Abudokirim
アブドキリム・アブドウプル
Masayoshi Ohira
真義 大平
Kensuke Okusa
健介 大草
Nobuo Seto
伸夫 瀬戸
Masahiro Furuno
正浩 古野
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GL Science Inc
Original Assignee
GL Science Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GL Science Inc filed Critical GL Science Inc
Priority to JP2005118750A priority Critical patent/JP4791750B2/en
Publication of JP2006296220A publication Critical patent/JP2006296220A/en
Application granted granted Critical
Publication of JP4791750B2 publication Critical patent/JP4791750B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Landscapes

  • Apparatus Associated With Microorganisms And Enzymes (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)

Abstract

<P>PROBLEM TO BE SOLVED: To simply and precisely obtain a target refined component from a biological sample in a short time by continuously making a biological sample liquid and various buffers flow. <P>SOLUTION: A target component is highly refined and separated by attaching a monolith structure having a physically solid silica skeleton to a disposable tube, etc., which is useable for centrifugal separator, making the biological sample flow, catching the sample in the monolith structure and eluting the sample. <P>COPYRIGHT: (C)2007,JPO&INPIT

Description

本発明は、DNAなどの分離精製方法及び分離精製機構に関するものである。   The present invention relates to a separation and purification method for DNA and the like and a separation and purification mechanism.

ヒトの全遺伝子配列解読が完了し、ゲノム研究は従来の構造解析から病態と関連した遺伝子の解明などの機能解析や、より具体的にターゲットを絞った創薬研究にその主流が移行しつつある。   Decoding the entire human gene sequence has been completed, and genomic research is shifting from conventional structural analysis to functional analysis such as elucidation of genes related to disease states and more specifically targeted drug discovery research .

これに伴い蓄積された遺伝情報(データーベース)をコンピュータで解析するバイオインフォマティクス(生命情報科学)の技術が急速に発達、活用されてきている。そのためSNPs解析(一塩基変異多型分析)、遺伝子発現解析では、生体試料からTemplate DNAを分離・精製することが必要となり、これまで以上の微量化、高性能化、効率化、高速化が求められている。   Along with this, bioinformatics (bioinformatics) technology for analyzing accumulated genetic information (database) with a computer has been rapidly developed and utilized. Therefore, in SNPs analysis (single nucleotide polymorphism analysis) and gene expression analysis, it is necessary to separate and purify Template DNA from biological samples, and there is a need for further miniaturization, higher performance, higher efficiency, and higher speed than before. It has been.

微量の生体試料から大量Template DNAを効率的に分離・精製する方法は未だ満足いくものが得られていないため、全血などの生体試料では、研究が制限されているのが現状である。また、全血サンプル中の白血球数は年令、性別、免疫状態、その他の保存状態など多くの要因により個体間でかなり変動し、DNA回収量にも影響する。この変動により、様々な白血球数をもつ全血サンプルから十分な量の高品質Template DNAを得るためには、微量試料を再現性のある適応性の高い精製テクノロジーが必要とされている。   Since a satisfactory method for efficiently separating and purifying a large amount of Template DNA from a small amount of biological sample has not yet been obtained, research on biological samples such as whole blood is currently limited. In addition, the number of white blood cells in a whole blood sample varies considerably among individuals due to many factors such as age, sex, immune status, and other storage conditions, and also affects the amount of DNA recovered. Due to this fluctuation, in order to obtain a sufficient amount of high-quality Template DNA from a whole blood sample having various white blood cell counts, a highly reproducible and adaptive purification technology for a minute amount of sample is required.

生体試料からTemplate DNAを分離・精製する方法としては、細胞溶解を行い、タンパク質を酵素分解し低分子化する前処理後に、種々の方法が提案されている。例えば、低分子化する前処理後、ガラス繊維フィルター上でカオトロピック物質の添加により、DNAを結合させ、次いで分離洗浄乾燥を経て溶離する単離方法が示されている。(非特許文献1参照)   As a method for separating and purifying Template DNA from a biological sample, various methods have been proposed after cell lysis and pretreatment for enzymatic degradation of the protein to lower its molecular weight. For example, an isolation method is shown in which DNA is bound by addition of a chaotropic substance on a glass fiber filter, followed by separation, washing and drying after pretreatment for reducing the molecular weight. (See Non-Patent Document 1)

又、ガラスパウダーを添加してDNAをガラスパウダーに結合させ、遠心分離して、ガラスパウダーを集め、洗浄、溶離し単離する方法が示されている(特許文献1、非特許文献2、非特許文献3、非特許文献4参照)。   In addition, a method of adding glass powder to bind DNA to glass powder, centrifuging, collecting the glass powder, washing, eluting and isolating is shown (Patent Document 1, Non-Patent Document 2, Non-Patent Document 2, (See Patent Document 3 and Non-Patent Document 4).

又、複合性生物出発材料、カオトロピック物質及びシリカ又はその誘導体を含む核酸結合性固相を混合し、 核酸を結合した固相を液体から分離し、洗浄し、核酸を溶離する方法が提案されている(特許文献2参照)。   Also proposed is a method in which a nucleic acid-binding solid phase containing a complex biological starting material, a chaotropic substance and silica or a derivative thereof is mixed, the solid phase to which the nucleic acid is bound is separated from the liquid, washed, and the nucleic acid is eluted. (See Patent Document 2).

カオトロピック試薬の存在下でDNAやRNAを吸着させる物理的メカニズムについては詳しくは明らかになっていないが、負に帯電した担体と、核酸との間にカチオン交換反応が起こると考えられている。従って精製の効率は、担体表面と生体試料の接触の効率とイコールと考えることができる。   Although the physical mechanism for adsorbing DNA and RNA in the presence of a chaotropic reagent is not clarified in detail, it is considered that a cation exchange reaction occurs between a negatively charged carrier and a nucleic acid. Therefore, the efficiency of purification can be considered as equal to the efficiency of contact between the carrier surface and the biological sample.

前記のどの担体を使用するにしろ、吸着させる担体を容器(カートリッジ、チップなど)に保持し、その容器に生体試料を通液し、吸着バッファー液で担体に核酸を吸着させ、その後洗浄液で核酸成分以外の夾雑物をカートリッジ外に追い出し、更にその後、溶出液を通液して核酸成分をその液と共に取り出す手順が一般的である。   Regardless of which carrier is used, the carrier to be adsorbed is held in a container (cartridge, chip, etc.), the biological sample is passed through the container, the nucleic acid is adsorbed to the carrier with the adsorption buffer solution, and then the nucleic acid is washed with the washing solution. A general procedure is to expel contaminants other than the components out of the cartridge, and then pass the eluate to take out the nucleic acid components together with the solution.

その他に、電気泳動やさまざまな抽出によってフラグメントDNAをアガロースゲルから精製することもよく行われるが、この方法は時間がかかり、得られたDNAも極めて希薄となり、塩や有機溶媒が含まれているため、更にエタノール沈殿で脱塩や濃縮する必要が生じるものである。又、ゲル濾過精製テクノロジーのような従来法では、分子量の類似した分子同士を分離することは非常に困難である。   In addition, fragment DNA is often purified from an agarose gel by electrophoresis or various extractions, but this method is time consuming and the resulting DNA is also very dilute and contains salts and organic solvents. Therefore, it is necessary to further desalinate or concentrate by ethanol precipitation. In addition, it is very difficult to separate molecules having similar molecular weights by conventional methods such as gel filtration purification technology.

しかし、これらのどの方法も、生体試料からの効率の高い精製や微量成分の精製に最適化されていないため高精製ができず目的を達成できなかったり、使い難いと言う欠点があり満足な結果が得られていない。   However, none of these methods are optimized for high-efficiency purification from biological samples and purification of trace components, so high purification cannot be achieved and the purpose cannot be achieved, and satisfactory results are found to be difficult to use. Is not obtained.

特開昭59−227744号公報JP 59-227744 A 特許第2680462号公報Japanese Patent No. 2680462 特表平8−5011321号公報JP-T-8-5011321 Nucleic Acids Research Vol.15 5507-5516(1987)Nucleic Acids Research Vol.15 5507-5516 (1987) Pvoc. Natl. Acad.Sci.USA Vol.76,615-619.(1979)Pvoc. Natl. Acad. Sci. USA Vol. 76, 615-619. (1979) Analytical Biochemistry Vol.121.382-387.(1982)Analytical Biochemistry Vol.121.382-387. (1982) Molecular cloning: A Laboratory Manual 188-190.(1982)Molecular cloning: A Laboratory Manual 188-190. (1982)

生体試料の精製を行う場合に、タンパクの酵素分解による前処理や溶液を加えての沈殿精製など、液を入れての取り扱いを行うため、液体を取り扱う容器が必需となる。当然使用する容器は小さい方が、容器表面積が小さくなり微量成分の取り扱いに便利となる。移し変えなど、使い勝手を考えると分離体をその容器に取り付ける工夫が必要である。その意味で、従来から見られる使い捨てタイプの容器にシリカゲルビーズを充填したものやシリカゲル繊維などを編み込んだフィルターを容器に取り付けた精製用カートリッジは適している。   When purifying a biological sample, a container for handling the liquid is indispensable because the liquid sample is handled by pretreatment by enzymatic degradation of protein or precipitation purification by adding a solution. Naturally, the smaller the container used, the smaller the surface area of the container and the more convenient the handling of trace components. Considering ease of use, such as relocation, it is necessary to devise a method for attaching the separated body to the container. In that sense, a conventional purification type cartridge in which a disposable type container filled with silica gel beads or a filter woven with silica gel fibers or the like is attached to the container is suitable.

粒子タイプでは、粒子径、表面積、細孔径などを自由に選択でき、種々のマトリクスが混在する種々の生体試料に対応できる利点がある。しかし、粒子をカートリッジ内に留めるフィルターが必要となる。フィルター部分は、精製に関与できないため、精製効率が悪くなる欠点がある。また、粒子空間を一定にできずバラツキは生じやすくなる。さらに粒子の溶出の可能性もある。そのため、安定した高精製には使用できず満足できない。   In the particle type, the particle diameter, the surface area, the pore diameter, etc. can be freely selected, and there is an advantage that it can be used for various biological samples in which various matrices are mixed. However, a filter is needed to keep the particles in the cartridge. Since the filter portion cannot participate in purification, there is a drawback that purification efficiency is deteriorated. Further, the particle space cannot be made constant, and variations are likely to occur. There is also the possibility of particle elution. Therefore, it cannot be used because it cannot be used for stable high purification.

一方、粒子を使用するのでなく、シリカゲル繊維で編み込まれたフィルターを容器に取り付けたカートリッジも提案されている。しかし、シリカゲル繊維などを網目状に織り込んだフィルターでは、弾力性が生じてしまい液の含み方で容積が変化してしまう。また、硬度が20Hk以下であり変形し易く取り扱いも不便である。特に、マトリクスを多く含む生体試料に適する遠心分離機を用いる場合には体積変化が顕著になり、生体試料では多量のマトリクスが混在するため、最初は粘性が高く、精製が進むにつれて、粘性が低下する傾向がある。そのため、繊維フィルターなどの抵抗圧力変化で液の流れる空間が変化してしまう分離体では、粘性が変化する生体試料などには適さない。   On the other hand, instead of using particles, a cartridge in which a filter knitted with silica gel fibers is attached to a container has been proposed. However, in a filter in which silica gel fibers or the like are woven into a mesh shape, elasticity is generated, and the volume changes depending on how the liquid is contained. Further, the hardness is 20 Hk or less, and it is easy to deform and is inconvenient to handle. In particular, when using a centrifuge suitable for biological samples containing a large amount of matrix, the volume change becomes significant, and a large amount of matrix is mixed in biological samples, so the viscosity is high at first, and the viscosity decreases as purification proceeds. Tend to. Therefore, a separated body such as a fiber filter in which the liquid flowing space changes due to a change in resistance pressure is not suitable for a biological sample or the like whose viscosity changes.

生体試料の精製には、液の流れる空間の変化が生じない固い分離体が必要とされる。重要な事は、圧力に対する液が流れる空間の変化であるが、取り扱いを考えると硬度30Hk以上の分離体が望まれる。   In order to purify a biological sample, a hard separator that does not cause a change in the space in which the liquid flows is required. What is important is the change in the space in which the liquid flows with respect to the pressure, but considering the handling, a separator with a hardness of 30 Hk or more is desired.

さらに、複雑な前処理を必要とする生体試料では、複数の工程が必要となり、その間に分離体が劣化してしまう。通液だけで、これらの工程を簡単に行なう事は、従来のような柔かい分離体では高い精製は望めない。   Furthermore, in a biological sample that requires complicated pretreatment, a plurality of steps are required, and the separator is deteriorated during that time. If these steps are simply performed by passing only liquid, high purification cannot be expected with a conventional soft separator.

また、カートリッジに分離体をどのように留めるという点も、重要な観点となる。弾力性のある樹脂製リングなどでこの固い分離体を容器等に留める方法は、一般的な精製においては、大きな問題とはならない。しかし、生体試料の場合は精製度の低い初期段階では粘性が高く、そのようなリングを取り付ける事は、液が通過する接液断面積を減らす事になり、適していない。血液などの微量成分を取り扱う場合には、精製を微量の場で行なう事が必需となりリングを取り付ける部分も作れない。   Another important point is how to keep the separator on the cartridge. The method of retaining this solid separated body in a container or the like with a resilient resin ring or the like is not a big problem in general purification. However, in the case of a biological sample, the viscosity is high at the initial stage where the degree of purification is low, and attaching such a ring is not suitable because it reduces the liquid contact cross section through which the liquid passes. When handling trace components such as blood, it is necessary to carry out purification in a small amount of space, and it is not possible to make a part for attaching a ring.

そのため、生体試料の精製には、フィルターや留めリングなどを用いない方法が適している。繊維フィルターなどでは不可能だが、硬度30Hk以上の固い分離体であれば、取り扱いが簡便になり、融着や圧入などでカートリッジに簡単に取り付けられる。圧入は、ボール盤の先に押し込み用のステンレス棒を取り付けて、樹脂製のカートリッジに分離体を押し込む事によって簡単にできるが、遠心に耐えうる装着が必要となり、硬度100Hk以上の分離体が望まれる。   Therefore, a method that does not use a filter or a retaining ring is suitable for purification of a biological sample. Although it is not possible with a fiber filter or the like, if it is a hard separated body having a hardness of 30 Hk or more, it is easy to handle and can be easily attached to the cartridge by fusion or press fitting. The press-fitting can be easily done by attaching a stainless steel rod to the end of the drilling machine and pushing the separating body into a resin cartridge, but it is necessary to be able to withstand centrifugation, and a separating body with a hardness of 100 Hk or more is desired. .

しかし、容器等の分離体を圧入する方法の問題点としては、生体試料の精製の場合には、ガラスや金属などの触媒作用が生じ易い容器は、避けられる事が多く、ポリエチレンやポリプロピレンなどの樹脂が使われる事が多くなってしまう。これらの容器では、熱収縮を受け易く、120℃滅菌などを念入りに行なう必要のある生体試料である大腸菌からのプラスミドDNA精製や生体試料からの微量成分から精製には、圧入しても加熱滅菌中に外れてしまう事もあり得る。   However, as a problem of the method of press-fitting a separated body such as a container, in the case of purification of a biological sample, a container that easily causes catalytic action such as glass or metal is often avoided, such as polyethylene and polypropylene. Resin is often used. These containers are susceptible to heat shrinkage and are sterilized by heating, even if they are pressed in, for purification of plasmid DNA from Escherichia coli, which is a biological sample that must be carefully sterilized at 120 ° C. It is possible that it will fall out.

そのため、カートリッジ樹脂を超音波などの振動で、一部を溶解させ、その部分通用液に分離体を融着する方法が適する事になる。分離体自身が、溶解しては分離体として意味が無くなるので、加熱下でも変化が生じない分離体が必要となる。取り扱いが容易な硬度30Hk以上の耐熱性の分離体が望まれる。   For this reason, a method in which a part of the cartridge resin is dissolved by vibration such as ultrasonic waves and the separator is fused to the partially used liquid is suitable. When the separator itself dissolves, it becomes meaningless as a separator, so a separator that does not change even under heating is required. A heat-resistant separator having a hardness of 30 Hk or more that is easy to handle is desired.

これらの観点をすべて、満足させる分離体として、生体試料成分の精製分離体としてモノリス構造体を提案する事ができる。   As a separator satisfying all of these viewpoints, a monolith structure can be proposed as a purified separator of biological sample components.

モノリス構造体は、主に、ゾル−ゲル法で作成することができる。即ち、テトラメトキシシランなどの金属アルコキシドやトリメトキシシランなどの反応性有機モノマーなどを単独または、混合して用いて、部分的に加水分解して、重縮合してコロイド状オリゴマーを作り(ゾルの生成)、更に加水分解して重合と架橋を促進させ、三次元構造網目を作る(ゲルの生成)ことで合成される。ゲル化は300℃以上で行なうので、融着熱でも変性する事が無い。   The monolith structure can be mainly produced by a sol-gel method. That is, a metal alkoxide such as tetramethoxysilane or a reactive organic monomer such as trimethoxysilane is used alone or in combination, and is partially hydrolyzed and polycondensed to form a colloidal oligomer (sol Production) and further hydrolyzed to promote polymerization and cross-linking to form a three-dimensional structure network (generation of gel). Since gelation is performed at 300 ° C. or higher, there is no denaturation even with heat of fusion.

また、ガラス分相によってもモノリス構造固相を作成できる。基本的には、ゾルーゲル法からのモノリス構造の合成と同様の有効性があるが、ゾルーゲルモノリスよりもマクロ細孔を大きく作る事ができるので、2次ミクロ細孔を内部表面に作る場合に有効である。更に、ガラス分相は、その組成より耐アルカリ性が高く、アルカリ洗浄による再生が出来ると言うメリットがある。   A monolithic solid phase can also be prepared by glass phase separation. Basically, it has the same effectiveness as the synthesis of the monolith structure from the sol-gel method, but it can make macropores larger than the sol-gel monolith, so it is effective when making secondary micropores on the inner surface. It is. Further, the glass phase separation has the advantage that it has higher alkali resistance than its composition and can be regenerated by alkali cleaning.

分相化は、500℃以上で行なわれるので、融着熱でも変性する事が無い。   Since the phase separation is performed at 500 ° C. or higher, there is no denaturation even with heat of fusion.

これらのモノリス構造体の作成方法は、HPLCにおけるカラムとして種々報告されており、20Mpa以上の耐圧性はあり、再現良く作られる事は知られている。   Various methods for producing these monolith structures have been reported as columns in HPLC, and have a pressure resistance of 20 Mpa or more and are known to be produced with good reproducibility.

生体試料では粘性が高く、圧力をかけても流路変化が生じず再現性良い精製ができる事が重要であるが、当然耐圧性があるほど、高速で液を流す事が可能になり精製時間が早まる。1Mpa以上の耐圧性を持つモノリス構造体が推奨できる。このモノリス構造体は、棒状に作成される事は知られており、それを機械的に切断し円盤状に切断する事で、本発明の分離体として用いる事ができる。   It is important for biological samples to be highly viscous and to be purified with good reproducibility without causing flow path changes even when pressure is applied. Naturally, the higher the pressure resistance, the faster the fluid can flow, and the purification time. Accelerates. A monolith structure having a pressure resistance of 1 Mpa or more can be recommended. This monolith structure is known to be formed in a rod shape, and can be used as a separator of the present invention by mechanically cutting it and cutting it into a disk shape.

取り扱いが簡便な30Hk以上の固さを持ち、かつ熱変性が生じず、生体試料の精製に適している。さらに、このモノリス構造体を800℃以上に焼成すると、骨格がガラス化し硬度が100Hk以上になり、圧入方法も使用できる事になる。   It has a hardness of 30Hk or more that is easy to handle and does not cause thermal denaturation, and is suitable for purification of biological samples. Furthermore, when this monolith structure is fired to 800 ° C. or higher, the skeleton becomes vitrified and the hardness becomes 100 Hk or higher, and a press-fitting method can be used.

また、ゾルゲル方法での作成では、自由な空間に作れるので、最初からカートリッジ等の容器内に直接モノリス構造体を作る事もできる。   In addition, since the sol-gel method can be used to create a free space, a monolith structure can be directly formed in a container such as a cartridge from the beginning.

微量生体試料用では、カートリッジチップの先端の小さな空間に作成できるので、特にデッドボリュームが生じずに適している。   For a small amount of biological sample, since it can be created in a small space at the tip of the cartridge chip, it is particularly suitable without causing a dead volume.

これらのモノリス構造体はすべて、シラノールを持つ事になり、従来から知られているDNA精製方法がそのまま使用できる事になる。   All of these monolith structures have silanols, and conventionally known DNA purification methods can be used as they are.

特に、生体試料成分を対象にする場合、目的の精製物によって粘度が異なり、液の流れのコントロールが重要であるが、モノリス構造体では液の流れるスルーポアを自由にコントロール生成できるので、生体試料の精製に適している。   In particular, in the case of biological sample components, the viscosity varies depending on the target purified product, and control of the flow of the liquid is important. However, in the monolith structure, the through-pores through which the liquid flows can be freely controlled and generated. Suitable for purification.

血液試料のような粘性の高い試料では10μm以上のスルーポアが適している。また、ゲル電気泳動で精製されたDNAの精製ならば、10μm未満のスルーポアでも行なえる。モノリス構造体では、液の通り道であるスルーポア以外にメソ孔を同時にコントロールする事ができる。生体試料である大腸菌から環状プラスミドDNAの精製の場合では、スルーポアの無いモノリス構造体が適している。   A through-pore of 10 μm or more is suitable for a highly viscous sample such as a blood sample. In addition, purification of DNA purified by gel electrophoresis can be performed with a through pore of less than 10 μm. In the monolith structure, the mesopores can be controlled at the same time other than the through-pore that is the passage of the liquid. In the case of purification of circular plasmid DNA from Escherichia coli, which is a biological sample, a monolith structure having no through pore is suitable.

生体試料の精製に適したモノリス構造体1は、40Hk以上の硬度を持ち熱安定性が高いので、生体試料の精製に適した種々容器に融着や圧入する事で取り付けられる。血液などの採取量が限定される生体試料液を対象にする場合には、生体試料液の取り扱いに良く使われる、図1(a)のようなピペットチップ2の先端に簡単に超音波融着ができる。そのため、図1(b)の遠心チューブ3と組み合わせて(図1(c))、遠心力で生体試料液をモノリス構造体内を通液させ、各種バッファーによって精製しながら、高純度な微量のゲノムDNAを得る。   Since the monolith structure 1 suitable for the purification of the biological sample has a hardness of 40 Hk or more and high thermal stability, it is attached by fusing or press-fitting into various containers suitable for the purification of the biological sample. When targeting biological sample liquids such as blood with limited collection volume, ultrasonic fusion is easily performed on the tip of the pipette tip 2 as shown in FIG. Can do. Therefore, in combination with the centrifuge tube 3 of FIG. 1 (b) (FIG. 1 (c)), the biological sample liquid is passed through the monolith structure by centrifugal force and purified with various buffers, while purifying with a small amount of highly pure genome. Obtain DNA.

さらに、多種の試料を同時精剤する場合には、96ウェルプレート4(図2)や384ウェルプレートなどの穴41,41…に夫々に自由にモノリス構造体の分離体42,42,42…を圧入や融着により設置することができる。この際、穴41等の通液部43に段部44を設けてモノリス構造体42を受け留めることは推奨される。又ここでは、ピペット、カートリッジ、遠心チューブ、ウェルプレート等の容器を総称してディスポーザル容器とする。   Furthermore, when simultaneously preparing various samples, the monolith structure separators 42, 42, 42,... Can be freely placed in the holes 41, 41, etc. of the 96-well plate 4 (FIG. 2) and the 384-well plate, respectively. Can be installed by press-fitting or fusing. At this time, it is recommended that the monolith structure 42 be received by providing the step portion 44 in the liquid passage portion 43 such as the hole 41. Here, containers such as pipettes, cartridges, centrifuge tubes, and well plates are collectively referred to as disposal containers.

本発明の主旨は、モノリス構造体が固いため、目的に応じた器具に自由に、圧入や融着などで取り付ける事で、遠心などの力でモノリス構造体内部に生体試料を流し、生体試料の精製が行なえる事であり、これらの例の形や融着方法に限定されないが、上記のような形態が最良である   The gist of the present invention is that the monolith structure is hard, so that the biological sample can be flowed into the monolith structure by force such as centrifugation by freely attaching it to the instrument according to the purpose by press-fitting or fusion. It is possible to purify, and it is not limited to the shape of these examples and the fusion method, but the above form is the best

また、ゾル−ゲル方法でのモノリス構造体では、ガラス表面を持つ空間の中ならば、自由にモノリス体を作成する事ができる。融着や圧入しなくても、図1のような先にモノリス体を形成させる事ができる。この場合にも液を流すため、圧力変化が生じ、耐圧性は必要となりモノリス構造体になっていないと生体試料の精製には適用できない。   Moreover, in the monolith structure body by the sol-gel method, a monolith body body can be freely created within a space having a glass surface. Even without fusing or press-fitting, a monolith body can be formed first as shown in FIG. In this case as well, since the liquid is allowed to flow, pressure changes occur, pressure resistance is required, and it cannot be applied to the purification of biological samples unless the monolith structure is formed.

全血では、遠心チューブに入れて、溶解・吸着溶液を加えて、70℃、15分間インキュベーションして、ボルテックスで混和して、全血を溶解する。遠心をかけた後、上澄み液をモノリスカラムにロードする。   For whole blood, put in a centrifuge tube, add lysis / adsorption solution, incubate at 70 ° C. for 15 minutes, mix by vortex to dissolve whole blood. After centrifugation, the supernatant is loaded onto a monolith column.

また、大腸菌培養液を遠心して、集菌して上清を捨て、沈殿物を別容器に回収する。次に、ミキシングして細胞を懸濁する。次に、溶解液を加えて細胞の溶解する。さらに、中和液を加えて転倒混和して中和する。次に、遠心した後、上澄み液をモノリスカラムにロードする。   Also, the E. coli culture solution is centrifuged, collected and discarded, and the precipitate is collected in a separate container. Next, the cells are suspended by mixing. Next, a lysis solution is added to lyse the cells. Further, neutralize by adding a neutralizing solution and mixing by inversion. Next, after centrifugation, the supernatant is loaded onto a monolith column.

これらのように、生体試料の場合では複雑な前処理工程が必要となる。その後に実際の精製工程となる。これらの工程は、血液、動物組織や大腸菌培養液などの対象生体試料によって、加える希釈液や溶解液や方法も異なる。また、遠心沈殿における精製回数も異なってくる。当然この前処理工程は少ない方が良いが、実際の精製工程において不純物が存在する事になり、液抵抗が増してしまう。固いモノリス構造体を用いた精製方法では、遠心をかけても流路変化が無く、十分対応できる。   As described above, in the case of a biological sample, a complicated pretreatment process is required. After that, it becomes the actual purification process. In these steps, the diluted solution, lysate, and method to be added differ depending on the target biological sample such as blood, animal tissue, or E. coli culture solution. In addition, the number of purifications in centrifugal precipitation also varies. Naturally, it is better that the number of the pretreatment steps is small, but impurities exist in the actual purification step, and the liquid resistance increases. In the purification method using a solid monolith structure, there is no change in the flow path even if centrifugation is performed, and this can be handled sufficiently.

1μl酢酸を添加した7%ポリエチレングリコール水溶液2mlに、テトラメトキシシラン1mlを、攪拌混合後、ポリカーボネート管に入れ両端をシールし、40℃でゲル化した。   1 ml of acetic acid was added to 2 ml of 7% polyethylene glycol aqueous solution, 1 ml of tetramethoxysilane was stirred and mixed, put into a polycarbonate tube and sealed at both ends, and gelled at 40 ° C.

ポリカーボネート管の大きさを変える事で、自由な径のモノリス構造体を得る事ができる。   By changing the size of the polycarbonate tube, a monolith structure with a free diameter can be obtained.

0.1規程アンモニア水溶液で置換し、数時間熟成しエタノールで置換乾燥後に、600℃に過熱し、スルーポア径30μm、メソポア径10nmの3次元網目構造の外径0.4mm径のシリカモノリス棒を得た。このモノリス棒を長さ1mmに切断し、硬度48Hkの分離体を得た。   Substitute with 0.1 standard ammonia aqueous solution, age for several hours, replace with ethanol and dry, then overheat to 600 ° C., and obtain a silica monolith rod with a three-dimensional network structure with a through pore diameter of 30 μm and a mesopore diameter of 10 nm and an outer diameter of 0.4 mm. Obtained. This monolith rod was cut to a length of 1 mm to obtain a separated body having a hardness of 48 Hk.

このモノリス分離体を10μl容量の市販ピペットチップに先に入れ、超音波融着器sonopet-150Bを用いて、0.2秒間押し込み、接触樹脂部を、超音波振動で溶解させ融着した。図1のような形状とした。   The monolith separated body was put in a commercially available pipette tip having a volume of 10 μl and pushed in for 0.2 seconds using an ultrasonic fusion device sonopet-150B, and the contact resin part was melted and fused by ultrasonic vibration. The shape is as shown in FIG.

電子顕微鏡による写真を示す。隙間が無く融着できる事が実証された。(図3)融着によるモノリス構造体の損傷が無い事が確認できた。   The photograph by an electron microscope is shown. It was proved that there was no gap and it could be fused. (FIG. 3) It was confirmed that there was no damage to the monolith structure due to fusion.

比較として、同じピペットチップの先に、ガラスウールを適量詰めたものを用意した。ガラスウールタイプの物では、融着は先が潰れて、超音波融着はできずに、詰めただけとした。   For comparison, an appropriate amount of glass wool was packed at the end of the same pipette tip. In the case of the glass wool type, the tip of the fusion was crushed, and ultrasonic fusion was not possible.

両方のピペットチップ各6本にトリス緩衝液を10μl入れて、3000rpmで遠心分離を行なったところ、ガラスウールタイプでは、6本中3本のガラスウールが抜けてしまった。融着した物では、6本共抜ける事は無かった。   When 6 μl of Tris buffer solution was added to each of both pipette tips and centrifuged at 3000 rpm, 3 out of 6 glass wools were lost in the glass wool type. In the case of the fused ones, it was not possible to miss all six.

同じように、生体試料である血液を5分の1に希釈して10μl入れて、3000rpmで遠心したところ、ガラスウールタイプでは6本中、6本ともガラスウールが抜けた。
モノリス構造体を融着した物では、6本とも抜ける事が無かった。
Similarly, when 10 μl of blood, which is a biological sample, was diluted to 1/5 and centrifuged at 3000 rpm, 6 out of 6 glass wool types lost glass wool.
None of the 6 monolith structures were missed.

さらに、同様に、10,000rpmで遠心を行なっても抜ける事が無く溶出液にモノリス構造体の破片は無かった。   Furthermore, similarly, even if it centrifuged at 10,000 rpm, it did not come out and there was no fragment of the monolith structure in the eluate.

血液に代表される生体試料では粘性が高く、高遠心が必要とされる場合が多いが、モノリス構造体を超音波融着した物では、高遠心まで使用でき、かつ、破砕することも無い事が確認できた。   Biological samples typified by blood are highly viscous and often require high centrifugation, but monolithic structures that are ultrasonically fused can be used up to high centrifugation and should not be crushed. Was confirmed.

10μl市販ピペットチップで先1mmのところまで、高純度パーヒドロポリシラザン(東燃(株)製、高純度品)の2%キシレン溶液(g/ml)を吸い、排出し空気中で80℃で24時間乾燥した。   A 2% xylene solution (g / ml) of high-purity perhydropolysilazane (manufactured by Tonen Co., Ltd., high-purity product) is sucked up to the point of 1 mm with a 10 μl commercial pipette tip, discharged and discharged in air at 80 ° C. for 24 hours. Dried.

この操作を5回繰り返して、ピペットチップの先1mm部分の表面に、石英膜を形成したピペットチップを得て、120℃で水蒸気滅菌を行なった。   This operation was repeated 5 times to obtain a pipette tip having a quartz film formed on the surface of the tip portion of 1 mm of the pipette tip, and steam sterilized at 120 ° C.

メチルトリメトキシシラン、共存物質としてのホルムアミドおよび触媒としての1mol/l硝酸水溶液をモル比で1:2.5:1.8の割合で混合した均一溶液を、上記処理を行ったピペットチップ先端1mmまで、吸い込み、先をシールテープで封をした。80℃でゲル化を行いピペットチップ先端1mm部分にモノリス構造体を作成した。   1 mm of the tip of the pipette tip subjected to the above treatment was mixed with a uniform solution in which methyltrimethoxysilane, formamide as a coexisting substance, and 1 mol / l nitric acid aqueous solution as a catalyst were mixed at a molar ratio of 1: 2.5: 1.8. Inhaled and sealed the tip with sealing tape. Gelation was performed at 80 ° C. to prepare a monolith structure at the 1 mm portion of the tip of the pipette tip.

スルーポア15μmのメソ孔の無いモノリス構造体が得られた。さらに必要に応じシリカ相を結合させる事により、メソ孔は作成でき、大きさは生体試料に適するように、コントロールできる。   A monolith structure having no mesopores with a through pore of 15 μm was obtained. Furthermore, mesopores can be created by combining silica phases as necessary, and the size can be controlled so as to be suitable for biological samples.

大腸菌によって作成される環状DNAでは、メソ孔の作成は必要無いが、今回は、血液対象とするため、さらにシリカ相を形成させメソ孔を作成した。   In the circular DNA produced by E. coli, it is not necessary to create a mesopore, but this time, in order to make it a blood target, a silica phase was further formed to create a mesopore.

5%トリメトキシシラン硝酸水溶液を1mm部分に吸い込み、80℃でゲル化する事で、モノリス表面にシリカ相が形成され、実施例1と同じくメソ孔が得られた。   A 5% trimethoxysilane nitric acid aqueous solution was sucked into a 1 mm portion and gelled at 80 ° C., whereby a silica phase was formed on the monolith surface, and mesopores were obtained as in Example 1.

ピペットチップ先端部分にモノリス構造体を作成したものを、実施例1と同様の方法で遠心をかけたが、抜ける事がなく、生体試料を流して使用できる事が実証できた。   The monolith structure prepared at the tip of the pipette tip was centrifuged by the same method as in Example 1, but it was demonstrated that it could be used by flowing a biological sample without coming off.

実施例1で作成したもの6本を、120℃で1時間滅菌した。サンプルチューブに新鮮全血を10μlを入れ、分解・吸着バッファー(8Mグアニジンチオシアン酸、0.8M酢酸カリウム)を20μl加え、70℃で15分間インキュベーションして、ボルテックスで混和し全血を溶解させた。   Six of those prepared in Example 1 were sterilized at 120 ° C. for 1 hour. Add 10 μl of fresh whole blood to the sample tube, add 20 μl of decomposition / adsorption buffer (8 M guanidine thiocyanate, 0.8 M potassium acetate), incubate for 15 minutes at 70 ° C., and mix by vortex to dissolve the whole blood. .

従来方法では、粘性を下げるために、RNA分解酵素、タンパク質分解酵素処理を行い次工程に行くが、本方法では、固いモノリス構造体を融着しているため、粘性の高い生体試料を流す事ができるため、これらの分解酵素を用いる必要が無い。この分解酵素は、PCRを阻害する事になり、これを用いないでも精製できる事は、重要なことである。   In the conventional method, in order to lower the viscosity, RNase and proteolytic enzyme treatment is performed and the next step is performed. However, in this method, since a hard monolith structure is fused, a highly viscous biological sample is allowed to flow. Therefore, it is not necessary to use these decomposing enzymes. This degrading enzyme inhibits PCR, and it is important that it can be purified without using it.

次に、融着したモノリス固相カラムを遠心チューブにセットし、10,000rpm遠心を1分間行いモノリス構造体内を通して、ゲノムDNAをモノリス構造体に濃縮捕集した。洗浄バッファー(0.5M酢酸カリウム、60%エタノール)にて1分間遠心し、モノリス構造体内を流して洗浄した。   Next, the fused monolith solid phase column was set in a centrifuge tube, centrifuged at 10,000 rpm for 1 minute, passed through the monolith structure, and concentrated and collected into the monolith structure. Centrifugation was performed for 1 minute in a washing buffer (0.5 M potassium acetate, 60% ethanol), and the monolith structure was washed.

次に、モノリス構造体をコレクションチューブにセットし、溶出バッファー(Tris−HCI10mM、pH8)を10μlを加えて10,000rpm遠心を1分間行いモノリス内を通して精製ゲノムDNAを溶出させた。   Next, the monolith structure was set in a collection tube, 10 μl of elution buffer (Tris-HCI 10 mM, pH 8) was added, and centrifugation was performed at 10,000 rpm for 1 minute to elute purified genomic DNA through the monolith.

それぞれの溶出液のA260/A280 が1.7以上である事が確認でき、その一部を取りゲル電気泳動の結果も確認できた。7本の精製結果とも再現性良く精製できている事が確認できた(図4 レーン1:pHYマーカー、レーン2〜7:PCR増幅産物再現性)。 It was confirmed that A 260 / A 280 of each eluate was 1.7 or more, and a part of them was taken to confirm the result of gel electrophoresis. It was confirmed that the seven purification results were purified with good reproducibility (FIG. 4, lane 1: pH marker, lanes 2-7: PCR amplified product reproducibility).

さらに、精製したゲノムDNAを用いて、ヒト β-Globin の遺伝子配列(408bp)をPCR増幅した。   Furthermore, the gene sequence (408 bp) of human β-Globin was PCR amplified using the purified genomic DNA.

わずか5μlの微量の血液試料からでも、本発明方法を用いて精製すると再現よくPCRできる事が確認できた(図5 レーン1:pHYマーカー、レーン2〜7:PCR増幅産物再現性)。   It was confirmed that PCR could be performed with good reproducibility when purified using the method of the present invention even from a very small amount of blood sample of 5 μl (FIG. 5, lane 1: pHY marker, lanes 2-7: reproducibility of PCR amplification product).

また、ABI Prism3730xlGeneticAnalyzerでシーケンスデータが確認できた(図6)。短時間精製でも、実際の生体試料分析に十分適用できる事が判明した。   Moreover, sequence data could be confirmed with ABI Prism 3730xlGeneticAnalyzer (FIG. 6). It was found that even a short purification could be applied to actual biological sample analysis.

実施例2で作成したものを、120℃で1時間滅菌した。サンプルチューブに凍結血液を3μl、6μl、9μl、12μlを入れ分解・吸着バッファー(6Mグアニジンチオシアン酸,0.8M酢酸カリウム)を各2倍量ずつ加え、70℃で15分間インキュベーションして、ボルテックスで混和し全血を溶解させた。   The one prepared in Example 2 was sterilized at 120 ° C. for 1 hour. Add 3 μl, 6 μl, 9 μl, and 12 μl of frozen blood to the sample tube, add 2 volumes each of decomposition / adsorption buffer (6 M guanidine thiocyanate, 0.8 M potassium acetate), incubate at 70 ° C. for 15 minutes, and vortex The whole blood was dissolved by mixing.

次に、融着したモノリス固相カラムを遠心チューブにセットし、10,000rpm遠心を1分間行いモノリス構造体内を通して、ゲノムDNAをモノリス構造体に濃縮捕集した。洗浄バッファー(0.5M酢酸カリウム,50%エタノール)にて1分間遠心し、モノリス構造体内を流して洗浄した。   Next, the fused monolith solid phase column was set in a centrifuge tube, centrifuged at 10,000 rpm for 1 minute, passed through the monolith structure, and concentrated and collected into the monolith structure. Centrifugation was performed for 1 minute in a washing buffer (0.5 M potassium acetate, 50% ethanol), and the monolith structure was washed by washing.

次に、コレクションチューブにセットし、溶出バッファー(RNAフリー水)を5μlを加えて10,000rpm遠心を1分間行いモノリス構造体内を通して溶出させた。   Next, it was set in a collection tube, 5 μl of elution buffer (RNA-free water) was added, and centrifugation was performed at 10,000 rpm for 1 minute to elute through the monolith structure.

それぞれの溶出液のA260/A280 が1.7以上である事が確認でき、ゲル電気泳動の結果を確認した。微量の3μl〜12μlまでの凍結血液でも、本発明方法を用いると簡単に精製できる事が確認できた(図7 レーン1:全血3μl、レーン2:全血6μl、レーン3:全血9μl、レーン4:全血12μl)。 It was confirmed that A 260 / A 280 of each eluate was 1.7 or more, and the result of gel electrophoresis was confirmed. It was confirmed that even a very small amount of 3 μl to 12 μl of frozen blood could be easily purified using the method of the present invention (FIG. 7 Lane 1: Whole blood 3 μl, Lane 2: Whole blood 6 μl, Lane 3: Whole blood 9 μl, Lane 4: whole blood 12 μl).

実施例1と同様に、ポリカーボネート管の径を大きくし、6mm径のシリカモノリス棒を作成し、1.5mmの厚さに切断した。これを図2のように、96ウエルプレート各々の穴に超音波融着器で融着した。   In the same manner as in Example 1, the diameter of the polycarbonate tube was increased to produce a silica monolith rod having a diameter of 6 mm and cut to a thickness of 1.5 mm. As shown in FIG. 2, this was fused to each hole of the 96-well plate with an ultrasonic fuser.

実施例3と同様の方法で、200μl新鮮血液から50μlの精製ゲノムDNAを溶出させた。   In the same manner as in Example 3, 50 μl of purified genomic DNA was eluted from 200 μl of fresh blood.

ゲル電気泳動の結果、図8(M:分子量マーカー、1〜4:本発明方法による再現性)のように再現良く精製ゲノムDNAが得られた。   As a result of gel electrophoresis, purified genomic DNA was obtained with good reproducibility as shown in FIG. 8 (M: molecular weight marker, 1-4: reproducibility by the method of the present invention).

その精製ゲノムDNAを、Human β‐globin 遺伝子100bp、400bpのPCR増幅を行なった結果、PCRされる事が確認でき、本発明の精製方法は精製度が高い事が実証できた。図9(M:分子量マーカー、レーン1,2:100bpのPCR増幅産物、レーン3,4:400bpのPCR増幅産物)に示す。   As a result of PCR amplification of the purified genomic DNA with 100 bp and 400 bp of human β-globin gene, it was confirmed that PCR was performed, and it was proved that the purification method of the present invention was highly purified. FIG. 9 (M: molecular weight marker, lane 1, 2: 100 bp PCR amplification product, lane 3, 4: 400 bp PCR amplification product).

実施例4と同様の方法で、400μl凍結血球から200μlの精製ゲノムDNAを溶出させた。ゲル電気泳動の結果、図10(M:分子量マーカー、1〜4:本発明方法による再現性)のような精製ゲノムDNAが得られた。   In the same manner as in Example 4, 200 μl of purified genomic DNA was eluted from 400 μl of frozen blood cells. As a result of gel electrophoresis, purified genomic DNA as shown in FIG. 10 (M: molecular weight marker, 1-4: reproducibility by the method of the present invention) was obtained.

その精製ゲノムDNAを、Human β‐globin 遺伝子740bpのPCR増幅を行なった結果、再現良くPCRされる事が確認でき、本発明の精製方法は精製度が高い事が実証できた(図11(M:分子量マーカー、1〜4:本発明方法で精製後のPCR増幅産物の再現性))。   As a result of PCR amplification of the purified genomic DNA of human β-globin gene 740 bp, it was confirmed that PCR was performed with good reproducibility, and it was proved that the purification method of the present invention was highly purified (FIG. 11 (M : Molecular weight marker, 1-4: Reproducibility of PCR amplification product after purification by the method of the present invention)).

1μl酢酸を添加した7%ポリエチレングリコール水溶液2mlに、テトラエトキシシラン1mlを、攪拌混合後、ポリカーボネート管に入れ両端をシールし、40℃でゲル化した。   1 ml of acetic acid was added to 2 ml of 7% polyethylene glycol aqueous solution and 1 ml of tetraethoxysilane was stirred and mixed, then put into a polycarbonate tube and sealed at both ends, and gelled at 40 ° C.

数時間熟成後しエタノールで置換乾燥後に、600℃に過熱し、スルーポア径10μm、メソポアが無いノンポーラスの3次元網目構造の外径7mm径のシリカモノリス棒を得た。このモノリス棒を長さ1mmに切断し、硬度42Hkの分離体を得た。   After aging for several hours and substitution-drying with ethanol, the mixture was heated to 600 ° C. to obtain a silica monolith rod having a through-pore diameter of 10 μm and a non-porous three-dimensional network structure having no mesopores and an outer diameter of 7 mm. This monolith rod was cut into a length of 1 mm to obtain a separated body having a hardness of 42 Hk.

さらに、固さを増すため、1150℃で焼結させ、硬度120Hkのモノリス構造分離体を得た。ひじょうに固い、円盤状のメソ孔の無いスルーポア10μmのモノリス体を得た。   Furthermore, in order to increase the hardness, sintering was performed at 1150 ° C. to obtain a monolith structure separator having a hardness of 120 Hk. A very hard monolithic body having a disk-like mesopore and a through-pore of 10 μm was obtained.

シリカモノリスは、高温で焼成する事で、液が流れる3次元網目構造の均一なスルーポア骨格を残したまま、強固なモノリス体となる。より強固になるため、物理的な力による圧入も可能となる。   Silica monolith is baked at a high temperature to form a strong monolith body while leaving a uniform through-pore skeleton with a three-dimensional network structure through which the liquid flows. Since it becomes stronger, press-fitting by physical force is also possible.

直立ボール盤の先に、外径5.5mmのステンレス無垢棒を取り付けた。スピンタイプディスポーザルカートリッジ5に強固なモノリス構造体51を入れ、回転させずに下に動かし、所定位置まで押し込み、図12のようなスピンタイプディスポーザルカートリッジを得た。   A solid stainless steel rod having an outer diameter of 5.5 mm was attached to the tip of an upright drilling machine. A strong monolith structure 51 was placed in the spin type disposal cartridge 5, moved downward without rotating, and pushed down to a predetermined position to obtain a spin type disposal cartridge as shown in FIG.

この強固なモノリス構造体では、特に複雑な処理が必要な生体試料成分に適している。例えば、大腸菌からの環状プラスミドDNAを精製は、細胞の懸濁、分解、中和処理後に精製工程に入る。しかし、前工程や試料状況によっては、不溶物が残存し、遠心で液を流す場合に急激な圧力変動が生じ易い。従来手法では、この大きな圧力変動によって、工程中に分離体の劣化が起こる事もあった。また、通りを良くするためには、なるべく薄い精製体の要求があるが、物理的に弱い精製体では困難である。本発明の焼成したモノリス構造体は、ひじょうに固く、薄く作る事も十分可能である。   This solid monolith structure is particularly suitable for biological sample components that require complex processing. For example, purification of circular plasmid DNA from E. coli enters the purification step after cell suspension, degradation, and neutralization. However, depending on the previous process and sample condition, insoluble matter remains, and a sudden pressure fluctuation is likely to occur when the liquid is flowed by centrifugation. In the conventional method, the large pressure fluctuation sometimes causes deterioration of the separator during the process. Further, in order to improve the street, there is a demand for a purified product as thin as possible, but it is difficult to use a physically weak product. The fired monolith structure of the present invention can be made very hard and thin.

固いモノリス構造体を用いる事で、このような複雑な前処理が必要とする生体試料の精製も遠心などで、モノリス構造体に液を通すだけで簡単に行なえる。   By using a solid monolith structure, purification of a biological sample that requires such a complicated pretreatment can be easily performed by simply passing a liquid through the monolith structure by centrifugation or the like.

生体試料である大腸菌培養液1mlをサンプルチューブにとり、10,000rpm、2秒間遠心し集菌後、上清を捨てる。沈澱物にRNA分解酵素および10mMのEDTAを含むトリスバッファー250μlを加えボルテクスミキシングを行い、細胞を懸濁する。次に、1%ラウリル硫酸ナトウムを含む水酸化カリウム水溶液を250μl加え混和する。さらに吸着バッファー(8Mグアニジンチオシアン酸、0.5M酢酸カリウム)を350μl加え混和し中和する。その後15,000rpmで、5分間遠心後不溶物を沈殿させる。   Take 1 ml of E. coli culture solution, which is a biological sample, in a sample tube, centrifuge at 10,000 rpm for 2 seconds, collect the cells, and discard the supernatant. To the precipitate, 250 μl of Tris buffer containing RNase and 10 mM EDTA is added, and vortex mixing is performed to suspend the cells. Next, 250 μl of potassium hydroxide aqueous solution containing 1% sodium lauryl sulfate is added and mixed. Further, 350 μl of adsorption buffer (8M guanidine thiocyanic acid, 0.5M potassium acetate) is added and mixed to neutralize. Thereafter, the insoluble matter is precipitated after centrifugation at 15,000 rpm for 5 minutes.

実施例7のモノリス固相カラムを遠心チューブにセットし、上澄み液を10,000rpm遠心を1分間行い、モノリス内を通して、プラスミドDNAをモノリスに濃縮捕集した。洗浄バッファー(0.3M酢酸カリウム、65%エタノール)500μlを加えて、1分間10,000rpmで遠心し、モノリス内を流して洗浄した。もう一度、洗浄バッファー(0.5M酢酸カリウム、60%エタノール)800μlを加えて、1分間10,000rpmで遠心し、モノリス内を流して洗浄した。さらに、1分間10,000rpmで空遠心を行いモノリス内の液を除いた。   The monolith solid phase column of Example 7 was set in a centrifuge tube, and the supernatant was centrifuged at 10,000 rpm for 1 minute, and the plasmid DNA was concentrated and collected in the monolith through the monolith. A washing buffer (0.3 M potassium acetate, 65% ethanol) (500 μl) was added, the mixture was centrifuged at 10,000 rpm for 1 minute, and washed through the monolith. Once again, 800 μl of a washing buffer (0.5 M potassium acetate, 60% ethanol) was added, centrifuged at 10,000 rpm for 1 minute, and washed through the monolith. The monolith was then centrifuged at 10,000 rpm for 1 minute to remove the liquid in the monolith.

次に、コレクションチューブにセットし、溶出バッファー(pH8水溶液)200μlを加えて10,000rpm遠心を1分間行い、モノリス内を通して溶出させた。   Next, the sample was set in a collection tube, 200 μl of elution buffer (pH 8 aqueous solution) was added, and centrifugation was performed at 10,000 rpm for 1 minute to elute through the monolith.

溶出された精製プラスミドDNAを電気泳動にて精製度を検査し、従来方法と比較した。   The purified plasmid DNA eluted was checked for purity by electrophoresis and compared with the conventional method.

図13は、大腸菌プラスミドDNA(環状DNA):pQE vectors 6xHistag constructsから精製環状DNAの電気泳動結果である。Mが分子量マーカーで、1が本発明方法で、2が従来方法である。従来方法に比べて、本発明方法の方が、4kbの精製プラスミドDNAが高い回収率で得られている事が判る。   FIG. 13 shows the results of electrophoresis of purified circular DNA from E. coli plasmid DNA (circular DNA): pQE vectors 6 × Histag constructs. M is a molecular weight marker, 1 is a method of the present invention, and 2 is a conventional method. It can be seen that 4 kb of purified plasmid DNA was obtained at a higher recovery rate than the conventional method.

従来方法は、シリカゲルメンブレンフィルターを使用しているQIAprep Spin Miniprep kit(キアゲン社)を用いて、キットに添付されている各種バッファーを用いて、添付プロトコール通り行なった。   The conventional method was carried out using QIAprep Spin Miniprep kit (Qiagen) using a silica gel membrane filter and using various buffers attached to the kit according to the attached protocol.

柔かい従来のメンブレンフィルターを用いて精製する時間は、約20分かかったが、固いモノリス構造体を用いた方法では約10分に短縮された。   The time required for purification using a soft conventional membrane filter took about 20 minutes, but was shortened to about 10 minutes in the method using a solid monolith structure.

図14は、大腸菌プラスミドDNA(環状DNA):pUC119 vectorsからの精製環状DNAの電気泳動結果である。Mが分子量マーカーで、従来方法が1で、本発明方法が2である。従来方法に比べて、本発明方法の方が、3.7kbの精製プラスミドDNAが高い精製度で得られている事が判る。   FIG. 14 shows the result of electrophoresis of purified circular DNA from Escherichia coli plasmid DNA (circular DNA): pUC119 vectors. M is a molecular weight marker, the conventional method is 1, and the method of the present invention is 2. It can be seen that the purified plasmid DNA of 3.7 kb is obtained with a higher degree of purification in the method of the present invention than in the conventional method.

これらのように、本発明の方法を用いると、生体試料である大腸菌から、環状プラスミドDNAを高い回収率で、高精製できる事が実証できた。   As described above, when the method of the present invention was used, it was proved that circular plasmid DNA could be highly purified from E. coli which is a biological sample with a high recovery rate.

(a)本発明一実施例側面図(b)本発明一実施容器側面図(c)本発明同上使用状態説明図(A) Side view of one embodiment of the present invention (b) Side view of one embodiment of the present invention (c) Use state explanatory drawing of the present invention 本発明−実施例斜面図The present invention-Example slope view (a)図1の要部電子顕微鏡拡大説明図(b)図3(a)の囲み部電子顕微鏡拡大説明図(A) Main part electron microscope enlarged explanatory view of FIG. 1 (b) Enclosed part electron microscope enlarged explanatory view of FIG. 3 (a) 本発明実施例の電気泳動図Electrophoretic diagram of the embodiment of the present invention 本発明実施例の電気泳動図Electrophoretic diagram of the embodiment of the present invention 本発明実施例 シーケンスデーターExample of the present invention Sequence data 本発明実施例の電気泳動図Electrophoretic diagram of the embodiment of the present invention 本発明実施例の電気泳動図Electrophoretic diagram of the embodiment of the present invention 本発明実施例の電気泳動図Electrophoretic diagram of the embodiment of the present invention 本発明実施例の電気泳動図Electrophoretic diagram of the embodiment of the present invention 本発明実施例の電気泳動図Electrophoretic diagram of the embodiment of the present invention 本発明実施例説明図Example of the present invention 本発明実施例の電気泳動図Electrophoretic diagram of the embodiment of the present invention 本発明実施例の電気泳動図Electrophoretic diagram of the embodiment of the present invention

符号の説明Explanation of symbols

1 モノリス構造体
2 ピペット
3 チューブ
4 ウェルプレート
5 カートリッジ
1 Monolith structure 2 Pipette 3 Tube 4 Well plate 5 Cartridge

Claims (6)

生体試料液を、容器に取付けたシラノール基を持つ3次元網目構造のモノリス構造の分離体を通過させることにより捕捉し、溶出させてDNAなどを分離精製する方法。 A method of separating and purifying DNA and the like by capturing and eluting a biological sample solution by passing it through a three-dimensional network monolithic separator having silanol groups attached to a container. 硬度30Hk以上の耐圧性モノリス構造体の分離体を用いる事を特徴とする請求項1のDNAなどの分離精製方法。 The method for separating and purifying DNA or the like according to claim 1, wherein a separated body of a pressure-resistant monolith structure having a hardness of 30 Hk or more is used. 焼成することにより硬化させたノンポーラスのモノリス構造体の分離体を用いることを特徴とする請求項1又は2記載のDNAなどの分離精製方法。 The method for separating and purifying DNA or the like according to claim 1 or 2, wherein a separated body of a non-porous monolith structure cured by firing is used. ディスポーザル容器等の通液部にモノリス構造体の分離体を生成形成させたことを特徴とするDNA等の分離精製機構。 A mechanism for separating and purifying DNA or the like, wherein a separation body of a monolith structure is formed and formed in a liquid passing part such as a disposal container. ディスポ-ザル容器等の通液部にモノリス構造体の分離体を融着固定させたことを特徴とするDNA等の分離精機構。 A separation mechanism of DNA or the like, wherein a monolith structure separated body is fused and fixed to a liquid passing part such as a disposable container. ウェルプレートの各穴にモノリス構造体の分離体を夫々設けたことを特徴とするDNA等の分離精製機構。 A mechanism for separating and purifying DNA or the like, wherein a monolith structure separated body is provided in each hole of a well plate.
JP2005118750A 2005-04-15 2005-04-15 Separation and purification method and separation and purification mechanism for DNA, etc. Active JP4791750B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2005118750A JP4791750B2 (en) 2005-04-15 2005-04-15 Separation and purification method and separation and purification mechanism for DNA, etc.

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2005118750A JP4791750B2 (en) 2005-04-15 2005-04-15 Separation and purification method and separation and purification mechanism for DNA, etc.

Publications (2)

Publication Number Publication Date
JP2006296220A true JP2006296220A (en) 2006-11-02
JP4791750B2 JP4791750B2 (en) 2011-10-12

Family

ID=37465089

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2005118750A Active JP4791750B2 (en) 2005-04-15 2005-04-15 Separation and purification method and separation and purification mechanism for DNA, etc.

Country Status (1)

Country Link
JP (1) JP4791750B2 (en)

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009150834A1 (en) 2008-06-12 2009-12-17 住友ベークライト株式会社 Method for preparation of sugar chain sample, sugar chain sample, and method for analysis of sugar chain
JP2010200661A (en) * 2009-03-03 2010-09-16 Toyobo Co Ltd Simple and rapid method for extracting nucleic acid
JP2011502251A (en) * 2007-10-31 2011-01-20 アコーニ バイオシステムズ Sample preparation equipment
WO2011158815A1 (en) * 2010-06-18 2011-12-22 東洋紡績株式会社 Method for simultaneous achievement of bacteriolysis of acid-fast bacterium and separation of nucleic acid from the bacterium
JP2013063064A (en) * 2011-08-29 2013-04-11 Sumitomo Bakelite Co Ltd Processing tool
JP2013165705A (en) * 2012-01-20 2013-08-29 Sumitomo Bakelite Co Ltd Treating tool
JP2014176393A (en) * 2014-06-17 2014-09-25 Toyobo Co Ltd Simple and rapid nucleic acid extraction method
WO2017119503A1 (en) * 2016-01-08 2017-07-13 株式会社ジーンデザイン Carrier for nucleic acid synthesis using inorganic porous material produced by sol-gel method

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH08501321A (en) * 1993-07-01 1996-02-13 キアゲン・ゲーエムベーハー Method for purifying and separating nucleic acid mixture by chromatography
JPH10182260A (en) * 1996-12-26 1998-07-07 Naohiro Soga Production of inorganic porous body
JP2002000255A (en) * 2000-06-22 2002-01-08 Hitachi Ltd Apparatus for extracting nucleic acid
JP2002513323A (en) * 1996-08-26 2002-05-08 マックス―プランク―ゲゼルシャフト・ツア・フェルデルング・デア・ヴィッセンシャフテン・アインゲトラーゲナー・フェアアイン Method for producing microporous element, microporous element produced by the method and use thereof
JP2002191351A (en) * 2001-10-19 2002-07-09 Hitachi Ltd Apparatus for purifying nucleic acid and chip for capturing nucleic acid
US20030102260A1 (en) * 1997-12-05 2003-06-05 Transgenomic, Inc. Non-polar media for polynucloetide separations
WO2004033470A2 (en) * 2002-10-04 2004-04-22 Whatman, Inc. Methods and materials for using chemical compounds as a tool for nucleic acid storage on media of nucleic acid purification systems
JP2004250247A (en) * 2003-02-18 2004-09-09 Dokai Chemical Industries Co Ltd Alkali-resistant chemically modified silica gel

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH08501321A (en) * 1993-07-01 1996-02-13 キアゲン・ゲーエムベーハー Method for purifying and separating nucleic acid mixture by chromatography
JP2002513323A (en) * 1996-08-26 2002-05-08 マックス―プランク―ゲゼルシャフト・ツア・フェルデルング・デア・ヴィッセンシャフテン・アインゲトラーゲナー・フェアアイン Method for producing microporous element, microporous element produced by the method and use thereof
JPH10182260A (en) * 1996-12-26 1998-07-07 Naohiro Soga Production of inorganic porous body
US20030102260A1 (en) * 1997-12-05 2003-06-05 Transgenomic, Inc. Non-polar media for polynucloetide separations
JP2002000255A (en) * 2000-06-22 2002-01-08 Hitachi Ltd Apparatus for extracting nucleic acid
JP2002191351A (en) * 2001-10-19 2002-07-09 Hitachi Ltd Apparatus for purifying nucleic acid and chip for capturing nucleic acid
WO2004033470A2 (en) * 2002-10-04 2004-04-22 Whatman, Inc. Methods and materials for using chemical compounds as a tool for nucleic acid storage on media of nucleic acid purification systems
JP2004250247A (en) * 2003-02-18 2004-09-09 Dokai Chemical Industries Co Ltd Alkali-resistant chemically modified silica gel

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011502251A (en) * 2007-10-31 2011-01-20 アコーニ バイオシステムズ Sample preparation equipment
WO2009150834A1 (en) 2008-06-12 2009-12-17 住友ベークライト株式会社 Method for preparation of sugar chain sample, sugar chain sample, and method for analysis of sugar chain
JP2010200661A (en) * 2009-03-03 2010-09-16 Toyobo Co Ltd Simple and rapid method for extracting nucleic acid
WO2011158815A1 (en) * 2010-06-18 2011-12-22 東洋紡績株式会社 Method for simultaneous achievement of bacteriolysis of acid-fast bacterium and separation of nucleic acid from the bacterium
JP2013063064A (en) * 2011-08-29 2013-04-11 Sumitomo Bakelite Co Ltd Processing tool
JP2013165705A (en) * 2012-01-20 2013-08-29 Sumitomo Bakelite Co Ltd Treating tool
JP2014176393A (en) * 2014-06-17 2014-09-25 Toyobo Co Ltd Simple and rapid nucleic acid extraction method
WO2017119503A1 (en) * 2016-01-08 2017-07-13 株式会社ジーンデザイン Carrier for nucleic acid synthesis using inorganic porous material produced by sol-gel method
JPWO2017119503A1 (en) * 2016-01-08 2018-10-25 株式会社ジーンデザイン Nucleic acid synthesis carrier using inorganic porous material produced by sol-gel method
JP7033923B2 (en) 2016-01-08 2022-03-11 株式会社ジーンデザイン Carrier for nucleic acid synthesis using an inorganic porous body produced by the sol-gel method

Also Published As

Publication number Publication date
JP4791750B2 (en) 2011-10-12

Similar Documents

Publication Publication Date Title
JP4791750B2 (en) Separation and purification method and separation and purification mechanism for DNA, etc.
US9624252B2 (en) Selective nucleic acid fragment recovery
Tan et al. DNA, RNA, and protein extraction: the past and the present
Emaus et al. Nucleic acid extraction: Fundamentals of sample preparation methodologies, current advancements, and future endeavors
CN1187362C (en) Solid-phase nucleic acid isolation
JP7576597B2 (en) Size-selective purification using thermoplastic silica nanomaterials
JP2009540868A (en) System for isolating biomolecules from samples
US20220025354A1 (en) Nucleic acid synthesis and purification device, use thereof, and nucleic acid synthesis and purification method
JP5433562B2 (en) Separation method of biomolecules using sulfolane
EP1719816B1 (en) Mechanism of separating and purifying dna
US20160376636A1 (en) Compositions and methods for sample preparation
WO1999051734A1 (en) Glass microfiber column and method for the preparation and purification of plasmid dna using the same
JP2023527475A (en) Nucleic acid extraction method and use
JP2017534289A (en) Chaotrope and volatile-free method for purifying nucleic acids from plasma
KR101380909B1 (en) Absorbents for purification of nucleic acid and a purification method using the absorbents
JP5614936B2 (en) Method for purifying nucleic acid using porous membrane with immobilized anion exchange group
JP4690656B2 (en) Nucleic acid separation and purification method and separation adsorbent
KR19990082777A (en) Glass microfiber column, method of preparation and purification for plasmide DNA using the same
Greene Isolation and purification of nucleic acids
WO2024131232A1 (en) Circular rna isolation and purification method
RU2595374C2 (en) Method for automated extraction with simultaneous purification of nucleic acids from several biological samples
CN106867994B (en) Rapid precipitation buffer solution applied to plasmid DNA extraction and application thereof
JP2010233579A (en) Separating and purification mechanism for dna or the like
JP4073430B2 (en) Nucleic acid recovery method

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20080226

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20101012

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20101213

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20110222

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110425

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20110712

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20110722

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20140729

Year of fee payment: 3

R150 Certificate of patent or registration of utility model

Ref document number: 4791750

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250